Page last updated: 2024-11-11

cefdinir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefdinir: A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefdinir : A cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6915944
CHEMBL ID927
CHEBI ID3485
SCHEMBL ID36995
MeSH IDM0159248
PubMed CID11655595
SCHEMBL ID16072816
MeSH IDM0159248

Synonyms (126)

Synonym
7beta-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido]-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
BIDD:GT0827
cefdinirum
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
MLS001304703
pd-134393
ci-983
fr-80482
omnicef
cefzon
fk-482
BSPBIO_002735
NCGC00178499-01
SPECTRUM5_001560
C08110
(6r,7r,z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DB00535
(6r,7r)-7-{2-(2-amino-thiazol-4-yl)-2-[(z)-hydroxyimino]-acetylamino}-8-oxo-3-vinyl-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefzon (tn)
cfdn
omnicef (tn)
D00917
cefdinir (jp17/usp/inn)
NCGC00095138-01
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(hydroxyiminoacetyl)amino)-3-ethenyl-8-oxo-, (6r-(6-alpha,7-beta(z)))-
cefdinyl
cefdinirum [inn-latin]
(-)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(z)-oxime
bmy 28488
fk 482
ci 983
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl) (hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-, (6r-(6alpha,7beta(z)))-
SPECTRUM1505208
HMS2093K20
chebi:3485 ,
bmy-28488
nsc-758926
CHEMBL927
cefdinir anhydrous
HMS1922L19
(6r,7r)-7-[[(2z)-2-(2-aminothiazol-4-yl)-2-hydroxyimino-acetyl]amino]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;cefdinir
A844075
(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C-2466
ceftinex
ci0fao63wc ,
nsc 758926
unii-ci0fao63wc
cefdinir [usan:usp:inn:ban]
dtxsid8046084 ,
tox21_113195
cas-91832-40-5
tox21_111730
dtxcid20820060
BCP9000503
pharmakon1600-01505208
nsc758926
MLS001424233
cefdirnir
AKOS015951262
CCG-39455
BCPP000293
cid_6915944
cefdinir [usp-rs]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl) (hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-, (6r-(6.alpha.,7.beta.(z)))-
cefdinir [mart.]
cefdinir [usp monograph]
cefdinir [jan]
cefdinir [who-dd]
cefdinir [inn]
cefdinir [usan]
cefdinir [orange book]
cefdinir [mi]
(-)-(6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 72-(z)-oxime
(6r,7r)-7-(((2z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefdinir [vandf]
syn-7-(2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid
S1605
BRD-K15766189-001-05-6
HY-B0136
CS-1925
SCHEMBL36995
AB01274720-01
cefdinir, antibiotic for culture media use only
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C3111
AB01274720_02
AB01274720_03
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(n-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefdinir, 97%
mfcd00865030
SR-05000001991-2
sr-05000001991
SR-05000001991-1
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, (6r,7r)-
SBI-0206739.P001
HMS3715F07
bdbm50248190
AKOS032960348
AS-35316
AMY22139
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-, (6r,7r)-
NCGC00178499-08
fk482
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2z)-2-(2-amino-4-thiazolyl)-2-(hydroxyimino)-1-oxoethyl)amino)-3-ethenyl-8-oxo-, (6r,7r)-
ci983
Q27263344
NCGC00178499-02
EN300-22411575
cefdinir (mart.)
cefdinir (usan:usp:inn:ban)
j01da42
(6r,7r)-7-((z)-2-(2-aminothiazol-4-yl)-(2-hydroxyimino)acetylamino)-8-oxo-3-vinyl-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6r,7r,z)-7-(2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefdinir (usp monograph)
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetyl)amino)-3-ethenyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
7beta-((2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(hydroxyimino)acetamido)-3-ethenyl-3,4-didehydrocepham-4-carboxylic acid
cefdinir (usp-rs)
(6r,7r)-7-(2-(2-amino-thiazol-4-yl)-2-((z)-hydroxyimino)-acetylamino)-8-oxo-3-vinyl-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cefdinirum (inn-latin)
cefdinir
91832-40-5
AKOS015994668
KS-1038 ,
SCHEMBL16072816
(7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-hydroxyiminoacetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Research Excerpts

Toxicity

Cefetamet pivoxil twice a day was as efficacious and safe as cefdinir 3 times a day for the treatment of acute bacterial rhinosinusitis.

ExcerptReferenceRelevance
" No difference was seen in the incidence of adverse events, in the incidence of diarrhea, or in the incidence of treatment withdrawals between the two groups."( Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis. The Cefdinir Bronchitis Study Group.
Griffin, TJ; Keyserling, CH; Puopolo, A; Sperling, MJ; Tack, KJ,
)
0.13
" Rates of adverse events and treatment discontinuations due to adverse events were examined."( Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.
Gwaltney, JM; Keyserling, C; Leigh, A; Rivas, P; Savolainen, S; Scheld, WM; Schenk, P; Sydnor, A; Tack, KJ, 1997
)
0.3
" The appearance of any adverse events was classified as associated or not associated with the medication of the study."( Efficacy and safety of cefdinir in the treatment of maxillary sinusitis.
Schenk, P; Steurer, M, 2000
)
0.31
" Cefdinir, an extended spectrum, third-generation cephalosporin is a safe and effective means of treating skin infections caused by these organisms, as well as many gram-negative pathogens."( Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
Devcich, KJ; París, MM, 2004
)
0.32
" In addition, it illustrates the potential for adverse outcomes in situations where antibiotics are used inappropriately or where first line antibiotics are not used for routine infections."( Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use.
Ahmad, J; Chen, J, 2008
)
0.35
" The overall adverse reaction rates of both drugs were 10."( Clinical Trial to Reconfirm the Efficacy and Safety of Cefetamet Pivoxil Treatment in Sinusitis Patients: A Double-Blind, Randomized, Parallel Designed, Multicenter, Active Comparator Study (CASIS Study).
Baek, BJ; Cho, JH; Cho, SH; Hwang, CS; In, SM; Jeong, JH; Kim, BG; Kim, DY; Kim, HJ; Kim, JK; Kim, KS; Kim, ST; Kim, YD; Kim, YM; Lee, HM; Lee, SH; Park, CS, 2023
)
0.91
"Cefetamet pivoxil twice a day was as efficacious and safe as cefdinir 3 times a day for the treatment of acute bacterial rhinosinusitis, which suggested that cefetamet pivoxil may be a suitable alternative to cefdinir."( Clinical Trial to Reconfirm the Efficacy and Safety of Cefetamet Pivoxil Treatment in Sinusitis Patients: A Double-Blind, Randomized, Parallel Designed, Multicenter, Active Comparator Study (CASIS Study).
Baek, BJ; Cho, JH; Cho, SH; Hwang, CS; In, SM; Jeong, JH; Kim, BG; Kim, DY; Kim, HJ; Kim, JK; Kim, KS; Kim, ST; Kim, YD; Kim, YM; Lee, HM; Lee, SH; Park, CS, 2023
)
0.91

Pharmacokinetics

The pharmacokinetic interaction between cefdinir and an angiotensin-converting enzyme inhibitor (captopril or quinapril) was investigated in rats. The pharmacokinetics parameters of cef dinir in children are similar to those obtained in adults using similar milligram per m2 doses.

ExcerptReferenceRelevance
"A pharmacokinetic study was performed on cefdinir (CFDN, FK482) 5% fine granules for pediatric use, and pharmacokinetic parameters were calculated."( [Pharmacokinetic studies on oral antibiotics in pediatrics. V. A pharmacokinetic study on cefdinir in pediatrics].
Iwai, N; Nakamura, H, 1992
)
0.28
"Bacteriological, pharmacokinetic and clinical studies on cefdinir (CFDN, FK482), a new oral cephalosporin, 5% and 10% granules, were performed in the field of pediatrics."( [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].
Hatakeyama, K; Hori, M; Nakano, K; Sakaguchi, N; Sugita, M; Toyonaga, Y; Yamazaki, M; Yamori, K, 1992
)
0.28
" Pharmacokinetic study: CFDN was evaluated pharmacokinetically in 4 male children aged 9 to 13."( [Pharmacokinetic and clinical studies of cefdinir in pediatric field].
Fukushima, N; Ishikawa, A; Takahashi, S; Takase, A; Wagatsuma, Y, 1990
)
0.28
" A pharmacokinetic study on CFDN was performed in 8 fasting patients whose ages ranged from 3 to 7 years."( [Clinical and pharmacokinetic evaluation of cefdinir in children].
Fujita, K; Iseki, K; Kakehashi, H; Murono, K; Sakata, H; Takahashi, Y; Yoshioka, H, 1990
)
0.28
"The pharmacokinetic profile of FK482 was studied in mice, rats, rabbits and dogs after oral dosing and compared with that of cefixime, cefaclor and cephalexin."( Pharmacokinetics of FK482, a new orally active cephalosporin, in animals.
Hatano, K; Hirose, T; Kikuchi, H; Kuwahara, S; Mine, Y; Nakamoto, S; Sakamoto, H; Shibayama, F, 1988
)
0.27
"The pharmacokinetic interaction between cefdinir and an angiotensin-converting enzyme inhibitor (captopril or quinapril) was investigated in rats."( Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats.
Jacolot, A; Petitjean, O; Tod, M, 1996
)
0.29
" The pharmacokinetic parameters of cefdinir in children are similar to those obtained in adults using similar milligram per m2 doses (300, 600 mg in adults = 7, 14 mg/kg in children, respectively)."( Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.
Guay, DR, 2000
)
0.31
"The pharmacodynamic and pharmacokinetic characteristics of cefdinir as described in this paper, as well as the results of the clinical trials program, support the use of this agent in the treatment of a wide variety of pediatric infectious diseases."( Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.
Guay, DR, 2000
)
0.31
" The time over MIC (T > MIC) of serum antibiotic concentrations were calculated with pharmacokinetic equation and MIC."( [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
Gao, L; Li, Y; Liu, J; Liu, Y; Lü, Y; Xiao, YH, 2004
)
0.32
"We performed pharmacokinetic analyses on 37 infants and children who were given cefdinir in dosages of 14 or 25 mg/kg once daily for 10 days, for the treatment of respiratory and skin or skin structure infections."( Cefdinir pharmacokinetics and tolerability in children receiving 25 mg/kg once daily.
Bowlware, KL; Ghaffar, F; Lozano-Hernandez, J; McCracken, GH, 2006
)
0.33
" The method was efficiently applied to a pharmacokinetic study in healthy volunteers."( Simultaneous determination of cefdinir and cefixime in human plasma by RP-HPLC/UV detection method: Method development, optimization, validation, and its application to a pharmacokinetic study.
Ahmad, L; Iqbal, Z; Javed, K; Khan, A; Khan, MI; Nasir, F; Shah, Y, 2011
)
0.37
" The developed method was applied successfully to the pharmacokinetic study of cefdinir after oral and intravenous administration."( Determination of cefdinir levels in rat plasma and urine by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics after oral and intravenous administration of cefdinir.
Jin, HE; Kim, CK; Kim, IB; Maeng, HJ, 2013
)
0.39
" This study was aimed at investigating the pharmacokinetic changes of cefdinir and cefditoren in AKI rats, and elucidating the possible molecular mechanisms."( Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats.
Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Wang, H, 2018
)
0.48
" On this basis, the pharmacokinetic changes of cefdinir and cefditoren were investigated in normal and AKI rats."( Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats.
Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Wang, H, 2018
)
0.48
" However, the pharmacokinetic changes of cefditoren were not observed."( Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats.
Huo, X; Liu, K; Liu, Z; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C; Wang, H, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31
" For this reason the anti-staphylococcal potency of the new drug, alone or in combination with other drugs was further characterized."( Antistaphylococcal activity of cefdinir, a new oral third-generation cephalosporin, alone and in combination with other antibiotics, at supra- and sub-MIC levels.
Debbia, EA; Marchese, A; Pesce, A; Saverino, D; Schito, GC, 1995
)
0.29

Bioavailability

Cefdinir (Cef) is an orally active Biopharmaceutics Classification System (BCS) class IV drug with incomplete absorption and low bioavailability (16-21%).

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, those compounds showed poor absorption rate after oral administration in rats."( [Studies on FK482 (Cefdinir). IV. Synthesis and structure-activity relationships of 7 beta-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]- 3-substituted cephalosporin derivatives].
Inamoto, Y; Kamimura, T; Sakane, K; Takaya, T, 1990
)
0.28
" The object of this study was to compare the bioavailability of cefdinir capsule (reference) and cefdinir granule (test) containing 100 mg of cefdinir."( Bioequivalence evaluation of cefdinir in healthy fasting subjects.
Chen, J; Jiang, B; Lou, H; Ruan, Z; Yu, L, 2012
)
0.38
"Cefdinir (Cef) is an orally active Biopharmaceutics Classification System (BCS) class IV drug with incomplete absorption and low bioavailability (16-21%)."( Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Patel, K; Patel, MH; Sawant, KK, 2016
)
0.43
" The oral bioavailability of CSDs was also evaluated in rats and compared with cefdinir powder suspension."( Cefdinir Solid Dispersion Composed of Hydrophilic Polymers with Enhanced Solubility, Dissolution, and Bioavailability in Rats.
Cho, HJ; Cho, KH; Choi, HG; Jee, JP; Kang, JY; Maeng, HJ; Shin, DY, 2017
)
0.46

Dosage Studied

Cefdinir is an alternative to other antimicrobial agents. It can be dosed once or twice daily for the treatment of upper and lower respiratory tract infections and skin and skin-structure infections. A simple, fast, specific, stability-indicating, and precise reversed-phase liquid chromatographic method was developed for the determination of cefdini's dosage forms.

ExcerptRelevanceReference
" Mean urinary peak concentrations of CFDN were observed during 2-4 hours after dosing in the before-meal group and during 6-8 hours in the after-meal group with values of 93."( [Pharmacokinetics and clinical effects of cefdinir 10% fine granules in pediatrics].
Aramaki, M; Handa, S; Kawakami, A; Motohiro, T; Oda, K; Oki, S; Sasaki, H; Tsumura, N; Yamada, S; Yoshinaga, Y, 1992
)
0.28
" Thus, dose-response between the 2 doses was observed in plasma levels and AUCs."( [Pharmacokinetics and clinical effects of cefdinir 5% fine granules in pediatrics].
Aramaki, M; Handa, S; Kawakami, A; Koga, T; Motohiro, T; Oki, S; Shimada, Y; Tsumura, N; Yamada, S; Yoshinaga, Y, 1990
)
0.28
"The pharmacokinetic profile of FK482 was studied in mice, rats, rabbits and dogs after oral dosing and compared with that of cefixime, cefaclor and cephalexin."( Pharmacokinetics of FK482, a new orally active cephalosporin, in animals.
Hatano, K; Hirose, T; Kikuchi, H; Kuwahara, S; Mine, Y; Nakamoto, S; Sakamoto, H; Shibayama, F, 1988
)
0.27
" influenzae showed that 6- to 12-mg/kg dosing was effective in reducing viable counts of these strains in blood by > or = 100-fold by 24 h after challenge."( In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models.
Cohen, MA; Gage, JW; Heifetz, CL; Mailloux, GB; Meservey, MA; Roland, GE; Wold, SA; Yoder, SL, 1994
)
0.29
" Two randomized, investigator-blind, multicenter trials (one in the United States and one in Europe) compared two dosage regimens of cefdinir (600 mg once a day for 10 days and 300 mg twice a day for 10 days) to amoxicillin-clavulanate (A-C) (500 mg three times a day for 10 days) for adult and adolescent patients with ACABS."( Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.
Gwaltney, JM; Keyserling, C; Leigh, A; Rivas, P; Savolainen, S; Scheld, WM; Schenk, P; Sydnor, A; Tack, KJ, 1997
)
0.3
" Based on its twice-a-day dosage and shorter course of therapy, leading to potentially greater patient compliance, cefdinir may be considered for use in the treatment of pharyngitis caused by GABHS."( Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.
Brink, DN; Gooch, WM; Henry, DC; Keyserling, CH; Tack, KJ, 1998
)
0.3
" Cefdinir was given orally to each patient in a dose of 100 mg, and blood was collected serially for 48 h after dosing in the test without dialysis and for 72 h in the test with dialysis."( Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.
Hishida, A; Kanamaru, M; Kitada, A; Nagashima, S; Obara, M; Ohishi, K, 1998
)
0.3
" This multicenter, randomized, controlled, double-masked study assessed the tolerability and efficacy of 2 dosing regimens of cefdinir in the treatment of pharyngitis due to GABHS."( Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.
Gooch, WM; Henry, D; Keyserling, CH; McCarty, J; Nemeth, MA; Tack, KJ, 1999
)
0.3
"Two dosage regimens of cefdinir were compared with amoxicillin/clavulanate for the treatment of suppurative acute otitis media (AOM) in children."( Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children.
Block, SL; Hedrick, JA; Keyserling, CH; McCarty, JM; Nemeth, MA; Tack, KJ, 2000
)
0.31
" Both dosing regimens of cefdinir were associated with significantly fewer gastrointestinal adverse reactions than was amoxicillin/clavulanate."( Comparative safety and efficacy of cefdinir vs amoxicillin/clavulanate for treatment of suppurative acute otitis media in children.
Block, SL; Hedrick, JA; Keyserling, CH; McCarty, JM; Nemeth, MA; Tack, KJ, 2000
)
0.31
"Cefdinir is a second-line alternative to first-line antimicrobial agents, with convenient once- or twice-daily dosing in the treatment of upper and lower respiratory tract infections and skin and skin-structure infections."( Cefdinir: an expanded-spectrum oral cephalosporin.
Guay, DR, 2000
)
0.31
" Decreased intestinal flora were noted in all the groups treated with S-1090 or CFDN at the end of the dosing period."( [Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (5)--Six-month repeated oral dose toxicity study and supplement study in rats].
Chihaya, Y; Furukawa, H; Itoh, F; Kato, I; Mizushima, Y; Nishimura, Y; Ohno, K; Omori, M; Sameshima, H; Ueno, M; Yabuuchi, K; Yahara, I; Yoshida, I, 2001
)
0.31
"Cefdinir is an alternative to other antimicrobial agents and can be dosed once or twice daily for the treatment of upper and lower respiratory tract infections and skin and skin-structure infections."( Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.
Guay, DR, 2002
)
0.31
" This article summarizes the pharmacokinetics, dosing schedule, adverse event profile, and efficacy data for cefdinir in adult and pediatric, populations in the treatment of uncomplicated skin and skin structure infections."( Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
Devcich, KJ; París, MM, 2004
)
0.32
"Children 6 months-4 years of age with AOM considered to be at risk for recurrent or persistent infection received large dosage cefdinir 25 mg/kg oral suspension once daily for 10 days."( A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection.
Arguedas, A; Dagan, R; Hoberman, A; Leibovitz, E; Paris, M; Pichichero, M, 2006
)
0.33
" The use of this later improves dissolution of tablet dosage form due to the lack of interconversion during tablet manufacture."( Cefdinir: A comparative study of anhydrous vs. monohydrate form. Microstructure and tabletting behaviour.
Alpegiani, M; Cabri, W; Ghetti, P; Justo-Erbez, A; Monedero-Perales, MC; Muñoz-Ruiz, A; Pérez-Martínez, JI; Pozzi, G; Villalón-Rubio, R, 2006
)
0.33
" Although guidelines continue to endorse amoxicillin as the preferred treatment, amoxicillin/clavulanate in high dosage would be the preferred treatment based on the otopathogen mix currently."( Otitis media.
Pichichero, ME, 2013
)
0.39
"0, temperature 30 °C, a shaking speed of 120 rpm, an inoculum dosage of 4 % (w/v) and an initial cefdinir concentration of 200 mg L(-1)."( Biodegradation of cefdinir by a novel yeast strain, Ustilago sp. SMN03 isolated from pharmaceutical wastewater.
Das, N; Salam, JA; Selvi, A, 2014
)
0.4
"0), inoculum dosage (1-7%), time (1-11 day) and cefdinir concentration (50-450 mg/L) was studied using a Box-Behnken design."( Potentiality of yeast Candida sp. SMN04 for degradation of cefdinir, a cephalosporin antibiotic: kinetics, enzyme analysis and biodegradation pathway.
Das, D; Das, N; Selvi, A, 2015
)
0.42
" The proposed method was successfully applied to the determination of CFN in bulk powder and pharmaceutical dosage forms."( Optimizing the spectrofluorimetric determination of cefdinir through a Taguchi experimental design approach.
Abou-Taleb, NH; El-Ashry, SM; El-Sherbiny, DT; El-Wasseef, DR, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
ketoximeOximes of ketones R2C=NOH (where R =/= H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency33.99720.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency19.95260.631035.7641100.0000AID504339
GLS proteinHomo sapiens (human)Potency25.11890.35487.935539.8107AID624170
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.48660.01237.983543.2770AID1645841
DNA polymerase eta isoform 1Homo sapiens (human)Potency87.02330.100028.9256213.3130AID588591; AID720502
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency56.23410.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
DNA polymerase kappa isoform 1Homo sapiens (human)Potency79.43280.031622.3146100.0000AID588579
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency7.94330.07578.474229.0628AID602233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SUMO-1Homo sapiens (human)IC50 (µMol)36.42500.64707.494715.9000AID624382; AID624383
low molecular weight phosphotyrosine protein phosphatase isoform cHomo sapiens (human)IC50 (µMol)19.60004.970011.256719.6000AID652005
carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 isoform 1Homo sapiens (human)IC50 (µMol)4.48002.05808.205241.3880AID540297
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)11.60000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Low molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)IC50 (µMol)21.50002.86009.633617.2000AID651700
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki20,100.00003.00006.47788.5000AID681347
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POsterior SegregationCaenorhabditis elegansEC50 (µMol)49.79402.201047.1808186.6810AID1964
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)33.25700.082031.0243168.9080AID1960
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)33.25700.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
acid phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
cytoplasmLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytosolLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytoplasmic side of plasma membraneLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
sarcolemmaLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular exosomeLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (270)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID207726Minimal inhibitory concentration against methicillin susceptible Staphylococcus aureus giorgio2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID423101Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558602Antimicrobial activity against Streptococcus pneumoniae isolate 33 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID567474Antimicrobial activity against gBLPACR-1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID682284TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM, Cefdinir: 2500 uM) in OCTN2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID558581Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279262Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3665 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID423257Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected male patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID423258Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected female patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID558606Antimicrobial activity against Streptococcus pneumoniae isolate 1147 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279266Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 3243 with L22 insertion 93SFRPRA94 mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID324993Antibacterial activity against Haemophilus haemolyticus ATCC 33390 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558610Antimicrobial activity against Streptococcus pneumoniae isolate 1424 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279271Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 2527 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID423237Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558582Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID423097Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558589Antimicrobial activity against Streptococcus pneumoniae 1 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID548235Antibacterial activity against beta-lactamase CTX-M ESBL-producing Enterobacteriaceae by twofold dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558594Antimicrobial activity against Streptococcus pneumoniae 6 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558597Antimicrobial activity against Streptococcus pneumoniae 9 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID548239Antibacterial activity against beta-lactamase CTX-M ESBL-producing Enterobacteriaceae assessed as percent susceptible isolates by twofold dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID324986Antibacterial activity against Haemophilus influenzae MSC06647 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423245Antibacterial activity against Moraxella catarrhalis isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID423261Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected inpatients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID438297Inhibition of penicillin-sensitive Streptococcus pneumoniae R6 PBP2X preincubated for 1 hr before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID531461Antibacterial activity against Streptococcus pneumoniae serotype 22 assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID279257Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279254Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81Y and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID681347TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID279256Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3009 with GyrA S81F and ParC D83N mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID531449Antibacterial activity against Streptococcus pneumoniae serotype 23A assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423251Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients within 2 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID535677Antimicrobial activity against beta-lactamase positive Haemophilus influenzae expressing fst1 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID208151Minimal inhibitory concentration against Streptococcus pneumonia PN010, penicillin resistant2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID558599Antimicrobial activity against Streptococcus pneumoniae 11 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID86134Minimal inhibitory concentration against Haemophilus influenza HIN003, beta lactamase producing resistant strain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID558617Antimicrobial activity against Streptococcus pneumoniae isolate 3260 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID681350TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID163920In vitro minimum inhibitory concentration required to produce antibacterial activity against Pseudomonas aeruginosa ATCC 278531996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID423098Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID423240Antibacterial activity against beta lactamase-positive Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558612Antimicrobial activity against Streptococcus pneumoniae isolate 2617 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423099Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558608Antimicrobial activity against Streptococcus pneumoniae isolate 1394 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID324992Antibacterial activity against Haemophilus haemolyticus MSC07286 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID324978Antibacterial activity against Haemophilus influenzae MSC01400 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID324989Antibacterial activity against rifampin-resistant Haemophilus influenzae RdRIF by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558621Antimicrobial activity against Streptococcus pneumoniae isolate 3346 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558624Antimicrobial activity against Streptococcus pneumoniae isolate 3455 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID423256Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected male patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID279263Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3676 with GyrA E85G, GyrB S478I and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID207361In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 743 MRSA1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID423235Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558583Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531460Antibacterial activity against Streptococcus pneumoniae serotype 33 assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID423238Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID521324Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06647 isolate harboring Asn526Lys mutation in penicillin-binding protein 3 by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID324988Antibacterial activity against Haemophilus influenzae MSC06663 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID208140Minimum inhibitory concentration for antibacterial activity against Streptococcus pneumoniae Q19 (pen s)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID531457Antibacterial activity against Streptococcus pneumoniae serotype 35B assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID531459Antibacterial activity against Streptococcus pneumoniae serotype 15A assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID279258Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID69035Minimal inhibitory concentration against Escherichia coli 3190Y2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID531456Antibacterial activity against Streptococcus pneumoniae serotype 19F assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID567470Antimicrobial activity against gBLNAS Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID535669Antimicrobial activity against beta-lactamase positive, ampicillin-clavulanic acid resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID423248Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 6 to 14 years of age after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID125085Minimal inhibitory concentration against Moraxella catarrhalis 252402000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID1625542Antimycobacterial activity against non-replicating Mycobacterium tuberculosis mc2 6220 harboring panCD/lysA deletion mutant incubated for 7 days measured at OD580 = 0.1 by two-fold serial dilution method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID531423Antibacterial activity against Streptococcus pneumoniae serotype 15A by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID324997Antibacterial activity against Haemophilus segnis ATCC 33393 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423104Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID324994Antibacterial activity against Haemophilus parainfluenzae ATCC 33392 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423236Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID535671Antimicrobial activity against beta-lactamase negative, ampicillin-resistant Haemophilus influenzae expressing fst1 mutant gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID324980Antibacterial activity against Haemophilus influenzae MSC07237 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423232Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID531458Antibacterial activity against Streptococcus pneumoniae serotype 23A assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID279273Antibacterial activity against Streptococcus pneumoniae assessed as period of suppression of bacterial growth2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID325001Antibacterial activity against rifampin and cefdinir-resistant Haemophilus influenzae RdRIF/MSC06647 mutant by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID423247Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 3 to 5 years of age after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558611Antimicrobial activity against Streptococcus pneumoniae isolate 1564 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID548247Antibacterial activity against beta-lactamase SHV or TEM ESBL-producing Enterobacteriaceae by twofold dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID521325Antimicrobial activity against beta lactamase-nonproducing ampicillin-resistant Haemophilus influenzae MSC06663 isolate harboring Met377Ile, Ser385Thr and Asn526Lys mutations in penicillin-binding protein 3 by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID558603Antimicrobial activity against Streptococcus pneumoniae isolate 37 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279269Antibacterial activity against levofloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81Y and ParC D83Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID324996Antibacterial activity against Haemophilus paraphrophilus ATCC 29241 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID52958In vitro minimum inhibitory concentration required to produce antibacterial activity against Citrobacter freundii 9021996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID535681Antimicrobial activity against beta-lactamase negative Haemophilus influenzae expressing fst1 gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID558622Antimicrobial activity against Streptococcus pneumoniae isolate 3374 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID535673Antimicrobial activity against beta-lactamase negative, ampicillin-resistant Haemophilus influenzae expressing fst1 mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID567471Antimicrobial activity against gLow-BLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID423102Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID324995Antibacterial activity against Haemophilus aphrophilus ATCC 33389 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID423233Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID324990Antibacterial activity against Haemophilus influenzae MSC07169 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID559859Antimicrobial activity against Streptococcus agalactiae clinical isolates by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.
AID324976Antibacterial activity against Haemophilus influenzae MSC02070 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID567472Antimicrobial activity against gBLNAR Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID567475Antimicrobial activity against gBLPACR-2 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID324998Antibacterial activity against Haemophilus parahaemolyticus ATCC 10014 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558631Antimicrobial activity against Streptococcus pneumoniae isolate 4755 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558618Antimicrobial activity against Streptococcus pneumoniae isolate 3263 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558605Antimicrobial activity against Streptococcus pneumoniae isolate 1146 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID67580Minimal inhibitory concentration against Enterococcus faecalis 292122000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID531454Antibacterial activity against Streptococcus pneumoniae serotype 6A/C assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID423234Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID324977Antibacterial activity against Haemophilus influenzae MSC01869 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423252Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 3 to 5 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558620Antimicrobial activity against Streptococcus pneumoniae isolate 3282 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID535679Antimicrobial activity against beta-lactamase negative Haemophilus influenzae expressing fst1 gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID531445Antibacterial activity against Streptococcus pneumoniae serotype 6A/C assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID324991Antibacterial activity against Haemophilus influenzae MSC07771 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID279260Antibacterial activity against azithromycin resistance selected Streptococcus pneumoniae 1077 with 23S rRNA A2058G mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279268Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 19 with GyrA S81F mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID531447Antibacterial activity against Streptococcus pneumoniae serotype 19F assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID423259Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected female patients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID324982Antibacterial activity against Haemophilus influenzae MSC02149 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID531455Antibacterial activity against Streptococcus pneumoniae serotype 3 assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID558626Antimicrobial activity against Streptococcus pneumoniae isolate 3481 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID207362In vitro minimum inhibitory concentration required to produce antibacterial activity against Staphylococcus aureus 887MSSA1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID558607Antimicrobial activity against Streptococcus pneumoniae isolate 1384 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID324981Antibacterial activity against Haemophilus influenzae MSC02104 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558615Antimicrobial activity against Streptococcus pneumoniae isolate 2874 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531418Antibacterial activity against Streptococcus pneumoniae serotype 6A/C by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID423250Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients more than 65 years of age after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID279264Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3676 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID324999Antibacterial activity against Haemophilus paraphrohaemolyticus ATCC 29237 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558613Antimicrobial activity against Streptococcus pneumoniae isolate 2686 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID279261Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3665 with GyrA S81Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID279255Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 3009 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID423241Antibacterial activity against beta lactamase-negative Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID324987Antibacterial activity against Haemophilus influenzae MSC06651 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558590Antimicrobial activity against Streptococcus pneumoniae 2 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1625538Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 2 days by Celltiter-Glo reagent based assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
AID535494Antimicrobial activity against beta-lactamase positive, ampicillin-clavulanic acid resistant Haemophilus influenzae expressing fst1 mutant gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID279265Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 3243 after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID531452Antibacterial activity against Streptococcus pneumoniae serotype 22 assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID423100Antibacterial activity against penicillin-resistant Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID567473Antimicrobial activity against gBLPAR-TEM1 Haemophilus influenzae by agar dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
AID558629Antimicrobial activity against Streptococcus pneumoniae isolate 3791 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID324983Antibacterial activity against Haemophilus influenzae MSC02022 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID423246Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients within 2 years of age after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID324979Antibacterial activity against Haemophilus influenzae MSC01855 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID531419Antibacterial activity against Streptococcus pneumoniae serotype 3 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID558592Antimicrobial activity against Streptococcus pneumoniae 4 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID279270Antibacterial activity against moxifloxacin resistance selected Streptococcus pneumoniae 24 with GyrA S81Y, GyrB P413S and ParC S79F mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID531420Antibacterial activity against Streptococcus pneumoniae serotype 19F by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID1625543Antimycobacterial activity against non-replicating Mycobacterium tuberculosis mc2 6220 harboring panCD/lysA deletion mutant incubated for 7 days measured at OD580 = 0.01 by two-fold serial dilution method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID68366In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterobacter cloacae 908SSI1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID558600Antimicrobial activity against Streptococcus pneumoniae 12 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID423262Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected outpatients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID1625544Antimycobacterial activity against replicating Mycobacterium tuberculosis mc2 6220 harboring panCD/lysA deletion mutant by two-fold serial dilution method2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.
AID558604Antimicrobial activity against Streptococcus pneumoniae isolate 1055 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558591Antimicrobial activity against Streptococcus pneumoniae 3 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID279259Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 1076 with ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID558596Antimicrobial activity against Streptococcus pneumoniae 8 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531451Antibacterial activity against Streptococcus pneumoniae serotype 33 assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID558628Antimicrobial activity against Streptococcus pneumoniae isolate 3681 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558598Antimicrobial activity against Streptococcus pneumoniae 10 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531421Antibacterial activity against Streptococcus pneumoniae serotype 35B by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID558619Antimicrobial activity against Streptococcus pneumoniae isolate 3275 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558625Antimicrobial activity against Streptococcus pneumoniae isolate 3458 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID324984Antibacterial activity against Haemophilus influenzae MSC01363 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID531417Antibacterial activity against Streptococcus pneumoniae serotype 19A by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID531424Antibacterial activity against Streptococcus pneumoniae serotype 33 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID423254Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 15 to 64 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID325000Antibacterial activity against Haemophilus influenzae Rd by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558601Antimicrobial activity against Streptococcus pneumoniae isolate 24 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID423253Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 6 to 14 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID558609Antimicrobial activity against Streptococcus pneumoniae isolate 1397 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID423255Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients more than 65 years of age assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID438298Inhibition of penicillin-resistant Streptococcus pneumoniae 5204 PBP2X preincubated for 4 hrs before addition of substrate (R)-[2-(benzoylamino)propionylsulfanyl]acetic acid2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
AID558627Antimicrobial activity against Streptococcus pneumoniae isolate 3587 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID679796TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 5 uM) in SKPT cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID521323Antimicrobial activity against rifampin-resistant Haemophilus influenzae Rd clone by broth dilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
AID423249Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients with 15 to 64 years of age after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID423103Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID423239Antibacterial activity against Haemophilus influenzae ATCC 49247 isolated from respiratory tract infected patients assessed as susceptible isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID548251Antibacterial activity against beta-lactamase SHV or TEM ESBL-producing Enterobacteriaceae assessed as percent susceptible isolates by twofold dilution method2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
AID67568In vitro minimum inhibitory concentration required to produce antibacterial activity against Enterococcus faecalis ATCC 292121996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID207513Minimal inhibitory concentration against methicillin resistant Staphylococcus aureus 772000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID531425Antibacterial activity against Streptococcus pneumoniae serotype 22 by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID679556TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 50 uM, Cefdinir: 10000 uM) in PEPT2-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID531453Antibacterial activity against Streptococcus pneumoniae serotype 19A assessed as percent resistant isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID163401Minimal inhibitory concentration against Proteus vulgaris 60592000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID208139In vitro minimum inhibitory concentration required to produce antibacterial activity against Streptococcus pneumoniae 1/37(pen r)1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID324985Antibacterial activity against Haemophilus influenzae MSC01432 by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID558630Antimicrobial activity against Streptococcus pneumoniae isolate 4747 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558595Antimicrobial activity against Streptococcus pneumoniae 7 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID531422Antibacterial activity against Streptococcus pneumoniae serotype 23A by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID423263Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected outpatients assessed as resistant isolates after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID531450Antibacterial activity against Streptococcus pneumoniae serotype 15A assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID680858TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM, Cefdinir: 10000 uM) in PEPT1-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID558623Antimicrobial activity against Streptococcus pneumoniae isolate 3412 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID558614Antimicrobial activity against Streptococcus pneumoniae isolate 2688 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID279272Antibacterial activity against gatifloxacin resistance selected Streptococcus pneumoniae 37 with GyrA S81Y, GyrB E474K and ParC S79Y mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID531446Antibacterial activity against Streptococcus pneumoniae serotype 3 assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID558616Antimicrobial activity against Streptococcus pneumoniae isolate 2880 by agar dilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID531448Antibacterial activity against Streptococcus pneumoniae serotype 35B assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID279267Antibacterial activity against clarithromycin resistance selected Streptococcus pneumoniae 3243 with 23S rRNA A2059T mutation after 10 antibiotic-free subcultures by macrodilution method2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID423260Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolated from respiratory tract infected inpatients after 20 to 24 hrs by broth microdilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
AID535675Antimicrobial activity against beta-lactamase positive Haemophilus influenzae expressing fst1 gene assessed as resistant isolates by microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers.
AID558593Antimicrobial activity against Streptococcus pneumoniae 5 by time-kill analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Comparative antipneumococcal activities of sulopenem and other drugs.
AID68853In vitro minimum inhibitory concentration required to produce antibacterial activity against Escherichia coli 259221996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Synthesis and structure-activity relationship of (lactamylvinyl)cephalosporins exhibiting activity against staphylococci, pneumococci, and enterococci.
AID95892Minimal inhibitory concentration against Klebsiella pneumonia 2011E2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and antibacterial activities of novel C(3)-aminopyrimidinyl substituted cephalosporins including against respiratory tract pathogens.
AID325003Antibacterial activity against rifampin and cefdinir-resistant Haemophilus influenzae RdRIF/MSC06663 mutant by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID531444Antibacterial activity against Streptococcus pneumoniae serotype 19A assessed as percent susceptible isolates by broth microdilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
AID325002Antibacterial activity against rifampin and cefdinir-resistant Haemophilus influenzae RdRIF/MSC06651 mutant by broth microdilution method2007Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5
Horizontal gene transfer of ftsI, encoding penicillin-binding protein 3, in Haemophilus influenzae.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (286)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.75)18.7374
1990's97 (33.92)18.2507
2000's98 (34.27)29.6817
2010's56 (19.58)24.3611
2020's30 (10.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 122.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index122.95 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index222.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (122.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials50 (18.38%)5.53%
Reviews2 (6.06%)6.00%
Reviews21 (7.72%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies27 (9.93%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other31 (93.94%)84.16%
Other174 (63.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (28)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis With Three Groups in Randomized Controlled Trial. [NCT03756324]Phase 2/Phase 3306 participants (Anticipated)Interventional2018-12-20Recruiting
A Pilot Study for a Randomized Trial of Antibiotics Versus Surgery for Treatment of Patients With Acute Uncomplicated Appendicitis [NCT02447224]Early Phase 130 participants (Anticipated)Interventional2015-03-31Completed
A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP) [NCT02891915]Phase 4385 participants (Actual)Interventional2016-12-02Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Fasting Conditions [NCT00835484]Phase 132 participants (Actual)Interventional2005-07-31Completed
A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Fasting Conditions [NCT00834574]Phase 132 participants (Actual)Interventional2005-02-28Completed
A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Non-Fasting Conditions [NCT00835549]Phase 132 participants (Actual)Interventional2005-03-31Completed
A Relative Bioavailability Study of 300 mg Cefdinir Capsules Under Non-fasting Conditions [NCT00834535]Phase 132 participants (Actual)Interventional2005-07-31Completed
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media [NCT00644943]Phase 4425 participants (Actual)Interventional2003-02-28Completed
A Comparative, Multi-Center, Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications [NCT00644774]Phase 4157 participants (Actual)Interventional2003-01-31Completed
Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Oral Antibiotics in the Community-based Treatment of Severe Acute Malnutrition in Malawian Children [NCT01000298]2,700 participants (Anticipated)Interventional2009-12-31Completed
A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Fo [NCT00883883]Phase 140 participants (Actual)Interventional2005-04-30Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
A Comparative, Multi-Center, Pediatric Taste Test Study of Cefdinir (Omnicef) Versus Amoxicillin Antibiotic Suspension Medications [NCT00644891]Phase 4158 participants (Actual)Interventional2003-01-31Completed
A Comparative, Single-Center, Pediatric Taste Test Study of Omnicef Versus Amoxicillin Antibiotic Suspension Medications [NCT00645125]Phase 4154 participants (Actual)Interventional2003-01-31Completed
An Open-Label, Safety and Efficacy Study of Cefdinir Oral Suspension, 25 mg/kg Once Daily, in Pediatric Subjects With Acute Otitis Media [NCT00645203]Phase 2/Phase 3447 participants (Actual)Interventional2002-07-31Completed
A Phase IV Comparative Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis [NCT00645073]Phase 4271 participants (Actual)Interventional2003-11-30Completed
A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and [NCT00882154]Phase 128 participants (Actual)Interventional2005-04-30Completed
A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and [NCT00882700]Phase 128 participants (Actual)Interventional2005-04-30Completed
A Comparison Study Between Cefdinir and Amoxicilline/Clavulanate in Patients With Acute Sinusitis and Assessment of Quality of Life (QOL) [NCT00147914]Phase 4100 participants (Actual)Interventional2005-02-28Completed
A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 250mg/5 ml Cefdinir (Test Formulation) and Omnicel 250mg/5 ml Powder For Oral Suspension (Reference Formulation) Each Given as a Single Oral Dose to Fo [NCT00882570]Phase 140 participants (Actual)Interventional2005-04-30Completed
A Clinical Trial to Re-confirm the Efficacy and the Safety of Cefetamet Pivoxil Formulation in Sinusitis Patients: Double Blinded, Randomized, Parallel Designed, Multi-center, Active Comparator Study (CASIS Study) [NCT04664803]Phase 4284 participants (Actual)Interventional2015-08-31Terminated
A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media [NCT00645112]Phase 4357 participants (Actual)Interventional2003-11-30Completed
A Comparative Study of the Safety, Tolerability, and Efficacy of Cefdinir and Cephalexin for the Treatment of Subjects With Mild to Moderate Uncomplicated Skin and Skin Structure Infections [NCT00234949]Phase 4380 participants Interventional2005-03-31Completed
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions [NCT03014687]Phase 4116 participants (Anticipated)Interventional2017-07-01Recruiting
Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting [NCT05702762]Phase 2160 participants (Anticipated)Interventional2022-10-01Recruiting
Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults [NCT03400735]Phase 450 participants (Anticipated)Interventional2017-11-01Recruiting
Postoperative Healthcare Utilization in Adenotonsillectomy Patients With Postoperative Antibiotic Administration Compared to Patients Without Antibiotic Administration [NCT01561703]58 participants (Actual)Interventional2012-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00834535 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00834535 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00834535 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00834574 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00834574 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00834574 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00835484 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00835484 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00835484 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00835549 (3) [back to overview]AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
NCT00835549 (3) [back to overview]AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
NCT00835549 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT01561703 (1) [back to overview]Healthcare Utilization
NCT02891915 (10) [back to overview]Adequate Clinical Response Rates (a Component of DOOR)
NCT02891915 (10) [back to overview]Adequate Clinical Response Rates (a Component of DOOR)
NCT02891915 (10) [back to overview]Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits
NCT02891915 (10) [back to overview]Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits
NCT02891915 (10) [back to overview]Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits
NCT02891915 (10) [back to overview]Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits
NCT02891915 (10) [back to overview]Number of Participants Reporting Solicited Symptoms
NCT02891915 (10) [back to overview]Number of Participants Reporting Solicited Symptoms
NCT02891915 (10) [back to overview]Resolution of Symptoms (a Component of DOOR)
NCT02891915 (10) [back to overview]Resolution of Symptoms (a Component of DOOR)

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00834535)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)11219.51
Omnicef® (Reference)11560.85

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00834535)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)10700.97
Omnicef® (Reference)11121.51

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00834535)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng/mL (Mean)
Cefdinir (Test)2081.37
Omnicef® (Reference)2045.43

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00834574)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)12553.808
Omnicef® (Reference)11680.224

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00834574)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)12426.232
Omnicef® (Reference)11568.479

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00834574)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng/mL (Mean)
Cefdinir (Test)2638.063
Omnicef® (Reference)2557.122

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00835484)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)14388.7
Omnicef® (Reference)14154.64

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00835484)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)13953.75
Omnicef® (Reference)13795.54

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00835484)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng/mL (Mean)
Cefdinir (Test)2995.84
Omnicef® (Reference)3063.65

[back to top]

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf. (NCT00835549)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)8103.237
Omnicef® (Reference)7933.332

[back to top]

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t. (NCT00835549)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng*h/mL (Mean)
Cefdinir (Test)8009.082
Omnicef® (Reference)7851.736

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax. (NCT00835549)
Timeframe: Blood samples collected over a 14 hour period.

Interventionng/mL (Mean)
Cefdinir (Test)1477.573
Omnicef® (Reference)1484.677

[back to top]

Healthcare Utilization

Questionnaire designed to evaluate healthcare utilization following surgery. Unit of measure will be the number of participants utilizing each category of healthcare. (NCT01561703)
Timeframe: 6 wks post-operative appointment

,
Interventionparticipants (Number)
Reported FeverMade a phone call to clinicER/UR/Clinic visit"Received additional antibiotic"Diagnostic workup at ER
Control168966
Intervention55200

[back to top]

Adequate Clinical Response Rates (a Component of DOOR)

Lack of adequate clinical response at OAV #1 is defined as the presence of a medically attended visit to an Emergency Department (ED) or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 5. (NCT02891915)
Timeframe: Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)

,
InterventionParticipants (Count of Participants)
Lack of Adequate Clinical ResponseED or Clinic VisitReceipt of Non-Study AntibioticHospitalizationSurgical Procedure
Short Course22200
Standard Course11100

[back to top]

Adequate Clinical Response Rates (a Component of DOOR)

Lack of adequate clinical response at OAV #2 is defined as the presence of a medically attended visit to an ED or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 18. (NCT02891915)
Timeframe: Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)

,
InterventionParticipants (Count of Participants)
Lack of Adequate Clinical ResponseED or Clinic VisitReceipt of Non-Study AntibioticHospitalizationSurgical Procedure
Short Course24200
Standard Course32300

[back to top]

Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits

This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 18 (NCT02891915)
Timeframe: Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)

,
InterventionParticipants (Count of Participants)
ED or Clinic VisitReceipt of Non-Study Antibiotic
Short Course2918
Standard Course3211

[back to top]

Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits

This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 5 (NCT02891915)
Timeframe: Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)

,
InterventionParticipants (Count of Participants)
ED or Clinic VisitReceipt of Non-Study Antibiotic
Short Course87
Standard Course72

[back to top]

Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits

This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 18 (NCT02891915)
Timeframe: Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)

,
InterventionParticipants (Count of Participants)
ED or Clinic VisitReceipt of Non-Study Antibiotic
Short Course42
Standard Course23

[back to top]

Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits

This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 5 (NCT02891915)
Timeframe: Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)

,
InterventionParticipants (Count of Participants)
ED or Clinic VisitReceipt of Non-Study Antibiotic
Short Course22
Standard Course11

[back to top]

Number of Participants Reporting Solicited Symptoms

This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 18 (NCT02891915)
Timeframe: Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)

,
InterventionParticipants (Count of Participants)
Any EventIrritabilityVomitingDiarrheaAllergic ReactionStomatitisCandidiasis
Short Course916719332217
Standard Course896024302167

[back to top]

Number of Participants Reporting Solicited Symptoms

This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 5 (NCT02891915)
Timeframe: Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)

,
InterventionParticipants (Count of Participants)
Any EventIrritabilityVomitingDiarrheaAllergic ReactionStomatitisCandidiasis
Short Course745211231514
Standard Course684311211534

[back to top]

Resolution of Symptoms (a Component of DOOR)

This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #1. (NCT02891915)
Timeframe: Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)

,
InterventionParticipants (Count of Participants)
Lack of Resolution of SymptomsFeverElevated respiratory rateCough
Short Course12227
Standard Course13174

[back to top]

Resolution of Symptoms (a Component of DOOR)

This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #2. (NCT02891915)
Timeframe: Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)

,
InterventionParticipants (Count of Participants)
Lack of Resolution of SymptomsFeverElevated respiratory rateCough
Short Course9026
Standard Course11315

[back to top]